Radius Health Inc.

+0.02 (+0.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)307.25M
Current PEN/A
Forward PE N/A
2yr Forward PE 162.5
See more stats
Estimates Current Quarter
Revenue$63.05 Million
Adjusted EPS-$0.18
See more estimates
10-Day MA$6.49
50-Day MA$10.70
200-Day MA$15.52
See more pivots

Radius Health Inc. Stock, NASDAQ:RDUS

22 Boston Wharf Road, 7th floor, Boston, Massachusetts 02210
United States of America
Phone: +1.617.551.4000
Number of Employees: 310


Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The companyâ??s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.